Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $54.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
